EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Myasthenia gravis and autoimmune overlap: Prognostic insight

Emel Oguz-Akarsu iD, Sarra El Hamida Lazrak, Deniz Sigirli iD, Gizem Gullu, Yasemin Dinç, Furkan Saridas iD, Necdet Karli

PLOS One · 2025

DOI: 10.1371/journal.pone.0334434 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Emel Oguz-Akarsu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Uludag School of Medicine, Bursa Uludag University, Bursa, Turkey. Hauptthemen laut MEDLINE: Myasthenia Gravis, Autoimmune Diseases. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Autoimmune diseases (ADs) frequently coexist with myasthenia gravis (MG), suggesting shared genetic and immunological mechanisms. However, the impact of comorbid ADs on MG prognosis remains unclear. This study aimed to investigate the prevalence, clinical characteristics, and prognosis of MG patients with comorbid ADs in a Turkish cohort.

Methods

We retrospectively analyzed 302 MG patients treated at a tertiary center between 2010 and 2024. Patients were grouped based on the presence of comorbid ADs. Clinical characteristics, disease severity, treatment response, and prognosis were compared.

Results

Among 302 MG patients, 41 (13.6%) had at least one comorbid AD, with autoimmune thyroid disease (AITD) being the most common (10.6%). ADs were more frequent in females. Patients with and without comorbid ADs showed no significant differences in MG severity, thymectomy rates, myasthenic exacerbations, or overall outcomes (p > 0.05). However, female patients with ADs experienced more frequent myasthenic exacerbations and had a higher rate of rituximab use (p < 0.05).

Conclusions

Comorbid ADs do not significantly impact MG severity or prognosis. Female MG patients with ADs have a higher frequency of myasthenic exacerbations and rituximab use, warranting further research. Early identification of ADs remains essential for optimal patient management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myasthenia GravisAutoimmune DiseasesHumansFemaleMalePrognosisMiddle AgedAdultRetrospective StudiesAgedComorbidityTurkeyRituximabYoung AdultPrevalenceSeverity of Illness Index

Substanzen

Rituximab

Autor:innen und Institutionen

  • Department of Neurology, Uludag School of Medicine, Bursa Uludag University, Bursa, Turkey.
  • Department of Statistics and Business Analytics, United Arab Emirates University, Al Ain, UAE.
  • Department of Biostatistics, Faculty of Medicine, Bursa Uludağ University, Bursa, Türkiye.

ORCID-Profile: Emel Oguz-Akarsu, Deniz Sigirli, Furkan Saridas

Zitieren

APA

Oguz-Akarsu, E., Lazrak, S. E. H., Sigirli, D., Gullu, G., Dinç, Y., Saridas, F., & Karli, N. (2025). Myasthenia gravis and autoimmune overlap: Prognostic insight. PLOS One. https://doi.org/10.1371/journal.pone.0334434

Vancouver

Oguz-Akarsu E, Lazrak SEH, Sigirli D, Gullu G, Dinç Y, Saridas F, et al. Myasthenia gravis and autoimmune overlap: Prognostic insight. PLOS One. 2025. doi:10.1371/journal.pone.0334434

BibTeX
@article{OguzAkarsu2025,
  author = {Oguz-Akarsu, Emel and Lazrak, Sarra El Hamida and Sigirli, Deniz and Gullu, Gizem and Dinç, Yasemin and Saridas, Furkan and Karli, Necdet},
  title = {Myasthenia gravis and autoimmune overlap: Prognostic insight},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0334434}
}
Kostenlos starten →